An experimental peptide-derived compound studied in animals for memory. FDA has found no human exposure data.
Key takeaway
Dihexa is a modified fragment of angiotensin IV, developed in the lab as a possible cognitive enhancer. Published research is in animals.
At a glance
| FDA status | Not FDA-approved |
|---|---|
| 503A compounding | No 503A pathway: nomination withdrawn after FDA safety review |
| Body areas | Brain, mood & sleep |
| Through ScriptMates | Information only |
| Open questions | 1 noted below |
What is dihexa?
Dihexa is a modified fragment of angiotensin IV, developed in the lab as a possible cognitive enhancer. Published research is in animals.
FDA says it has not identified any human exposure data for dihexa by any route.
Dosage forms
No FDA-approved dosage form. A standardized dosage form for human use was not confirmed from the sources below.
Is dihexa FDA-approved?
Not FDA-approved. Dihexa acetate was nominated for the 503A bulks list and placed in Category 2 over safety concerns; the nomination was later withdrawn. FDA notes it has no, or only limited, safety information for the proposed uses.
Can it be prescribed through ScriptMates?
No 503A pathway: nomination withdrawn after FDA safety review. A partner pharmacy lists it, but it has no lawful 503A pathway today (nomination withdrawn after FDA safety review).
What we could not confirm
- Dihexa is a peptidomimetic (peptide-derived) rather than a true peptide.
Sources
- FDA: Bulk substances that may present significant safety risks (Category 2 and withdrawn nominations)
- FDA: Bulk drug substances nominated under 503A, Categories 1–3 (May 14, 2026)
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.